Harmony Biosciences Holdings, Inc. Announces 2024 Annual Meeting of Stockholders
Ticker: HRMY · Form: DEF 14A · Filed: Apr 11, 2024 · CIK: 1802665
| Field | Detail |
|---|---|
| Company | Harmony Biosciences Holdings, INC. (HRMY) |
| Form Type | DEF 14A |
| Filed Date | Apr 11, 2024 |
| Risk Level | low |
| Pages | 16 |
| Reading Time | 19 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: Harmony Biosciences, HRMY, DEF 14A, Annual Meeting, Proxy Statement
TL;DR
Harmony Biosciences Holdings, Inc. will hold its virtual 2024 Annual Meeting on May 29, 2024, to elect directors and ratify auditor appointments.
AI Summary
Harmony Biosciences Holdings, Inc. (HRMY) filed a Proxy Statement (DEF 14A) with the SEC on April 11, 2024. Harmony Biosciences Holdings, Inc. will hold its 2024 annual meeting of stockholders on May 29, 2024, at 1:00 p.m. Eastern Time. The meeting will be conducted virtually via live audio webcast at www.virtualshareholdermeeting.com/HRMY2024. Key purposes of the meeting include electing three Class I directors, ratifying the appointment of Deloitte & Touche LLP as independent auditors for FY2024, and transacting other business. The board of directors has fixed April 1, 2024, as the record date for determining stockholders entitled to notice of and to vote at the meeting. The company believes a virtual meeting offers expanded access, improved communication, and cost savings for stockholders.
Why It Matters
For investors and stakeholders tracking Harmony Biosciences Holdings, Inc., this filing contains several important signals. The shift to a virtual meeting format aims to increase stockholder accessibility and engagement while reducing costs. The election of directors and ratification of the independent auditor are critical governance activities that impact the company's oversight and financial reporting integrity.
Risk Assessment
Risk Level: low — Harmony Biosciences Holdings, Inc. shows low risk based on this filing. The filing is a routine proxy statement (DEF 14A) and does not contain new financial or operational information, indicating low immediate risk.
Analyst Insight
Stockholders should review the proxy materials to understand director nominees, auditor ratification, and voting procedures for the upcoming annual meeting.
Key Numbers
- 3 — Class I Directors (To be elected at the Annual Meeting)
- 2027 — Director Term End (Until annual meeting of stockholders in 2027)
- 2024 — Fiscal Year End (For which Deloitte & Touche LLP is appointed as auditor)
Key Players & Entities
- Harmony Biosciences Holdings, Inc. (company) — Registrant name
- Deloitte & Touche LLP (company) — Independent registered public accounting firm
- May 29, 2024 (date) — Date of Annual Meeting
- April 1, 2024 (date) — Record date for the Annual Meeting
- 1:00 p.m. Eastern Time (time) — Time of Annual Meeting
FAQ
When did Harmony Biosciences Holdings, Inc. file this DEF 14A?
Harmony Biosciences Holdings, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 11, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Harmony Biosciences Holdings, Inc. (HRMY).
Where can I read the original DEF 14A filing from Harmony Biosciences Holdings, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Harmony Biosciences Holdings, Inc..
What are the key takeaways from Harmony Biosciences Holdings, Inc.'s DEF 14A?
Harmony Biosciences Holdings, Inc. filed this DEF 14A on April 11, 2024. Key takeaways: Harmony Biosciences Holdings, Inc. will hold its 2024 annual meeting of stockholders on May 29, 2024, at 1:00 p.m. Eastern Time.. The meeting will be conducted virtually via live audio webcast at www.virtualshareholdermeeting.com/HRMY2024.. Key purposes of the meeting include electing three Class I directors, ratifying the appointment of Deloitte & Touche LLP as independent auditors for FY2024, and transacting other business..
Is Harmony Biosciences Holdings, Inc. a risky investment based on this filing?
Based on this DEF 14A, Harmony Biosciences Holdings, Inc. presents a relatively low-risk profile. The filing is a routine proxy statement (DEF 14A) and does not contain new financial or operational information, indicating low immediate risk.
What should investors do after reading Harmony Biosciences Holdings, Inc.'s DEF 14A?
Stockholders should review the proxy materials to understand director nominees, auditor ratification, and voting procedures for the upcoming annual meeting. The overall sentiment from this filing is neutral.
How does Harmony Biosciences Holdings, Inc. compare to its industry peers?
Harmony Biosciences Holdings, Inc. operates in the pharmaceutical preparations industry, focusing on treatments for rare diseases.
Are there regulatory concerns for Harmony Biosciences Holdings, Inc.?
The filing is a proxy statement (DEF 14A) under the Securities Exchange Act of 1934, requiring disclosure of information for shareholder voting.
Industry Context
Harmony Biosciences Holdings, Inc. operates in the pharmaceutical preparations industry, focusing on treatments for rare diseases.
Regulatory Implications
The filing is a proxy statement (DEF 14A) under the Securities Exchange Act of 1934, requiring disclosure of information for shareholder voting.
What Investors Should Do
- Review the list of director nominees and their qualifications.
- Understand the proposal to ratify Deloitte & Touche LLP as the independent auditor for fiscal year 2024.
- Follow instructions for virtual attendance and electronic voting at the May 29, 2024 Annual Meeting.
Key Dates
- 2024-05-29: Annual Meeting of Stockholders — Election of directors, ratification of auditors, and other business.
- 2024-04-01: Record Date — Determines stockholders eligible to vote at the Annual Meeting.
Year-Over-Year Comparison
This is a DEF 14A filing, which is a routine proxy statement and does not represent a change from previous filings in terms of new financial or operational data.
Filing Stats: 4,812 words · 19 min read · ~16 pages · Grade level 12.2 · Accepted 2024-04-11 08:17:08
Filing Documents
- ny20020531x1_def14a.htm (DEF 14A) — 1308KB
- hrmy_audit.jpg (GRAPHIC) — 4KB
- hrmy_chair.jpg (GRAPHIC) — 5KB
- hrmy_chairaudit.jpg (GRAPHIC) — 6KB
- hrmy_member.jpg (GRAPHIC) — 4KB
- logo_harmony.jpg (GRAPHIC) — 51KB
- logo_harmonyx1.jpg (GRAPHIC) — 39KB
- logo_harmonyx2.jpg (GRAPHIC) — 18KB
- ny20020531x1_pc01.jpg (GRAPHIC) — 593KB
- ny20020531x1_pc02.jpg (GRAPHIC) — 510KB
- ny20020531x1_pvp01.jpg (GRAPHIC) — 75KB
- ny20020531x1_pvp02.jpg (GRAPHIC) — 65KB
- ny20020531x1_pvp03.jpg (GRAPHIC) — 64KB
- 0001140361-24-019230.txt ( ) — 5812KB
- hrmy-20240529.xsd (EX-101.SCH) — 7KB
- hrmy-20240529_def.xml (EX-101.DEF) — 9KB
- hrmy-20240529_lab.xml (EX-101.LAB) — 21KB
- hrmy-20240529_pre.xml (EX-101.PRE) — 13KB
- ny20020531x1_def14a_htm.xml (XML) — 190KB
Executive Compensation Tables
Executive Compensation Tables 35 Director Compensation 47 Equity Compensation Plan Information Table 50 i TABLE OF CONTENTS PAGE
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 51 RELATED PERSON TRANSACTIONS 53 Policies and Procedures for Related Person Transactions 54 OTHER MATTERS 55 Delinquent Section 16(a) Reports 55 Fiscal Year 2023 Annual Report and SEC Filings 55 Special Note Regarding Forward-Looking Statements 55 ii TABLE OF CONTENTS HARMONY BIOSCIENCES HOLDINGS, INC. PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS To Be Held at 1:00 p.m. Eastern Time on May 29, 2024 This proxy statement and the enclosed form of proxy are furnished in connection with the solicitation of proxies by our board of directors for use at the 2024 annual meeting of stockholders of Harmony Biosciences Holdings, Inc., a Delaware corporation ("Harmony" or the "Company"), and any postponements, adjournments or continuations thereof (the "Annual Meeting"). The Annual Meeting will be held on May 29, 2024 at 1:00 p.m. Eastern Time. The Annual Meeting will be a virtual meeting of stockholders, which will be conducted via live audio webcast. You will be able to virtually attend and listen to the Annual Meeting live, submit questions and vote your shares electronically at the Annual Meeting. In order to virtually attend and vote at the Annual Meeting, please follow the instructions in the section titled "Questions and Answers About the Proxy Materials and Our Annual Meeting: What do I need to do to attend the Annual Meeting virtually?" on page 3 . The Notice containing instructions on how to access this proxy statement and our annual report is first being mailed on or about April 11, 2024 to all stockholders entitled to vote at the Annual Meeting. IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON May 29, 2024: The proxy statement for the Annual Meeting and the Annual Report on Form 10-K for the fiscal year ended December 31, 2023 are available free of charge at https://www.proxyvote.com. You